Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
118.39
-1.07 (-0.90%)
Jan 17, 2025, 4:00 PM EST - Market closed
Revvity Employees
Revvity had 11,500 employees as of December 31, 2023. The number of employees decreased by 5,200 or -31.14% compared to the previous year.
Employees
11,500
Change (1Y)
-5,200
Growth (1Y)
-31.14%
Revenue / Employee
$236,657
Profits / Employee
$22,113
Market Cap
14.41B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 11,500 | -5,200 | -31.14% |
Dec 31, 2022 | 16,700 | 0 | - |
Dec 31, 2021 | 16,700 | 2,700 | 19.29% |
Dec 31, 2020 | 14,000 | 1,000 | 7.69% |
Dec 31, 2019 | 13,000 | 500 | 4.00% |
Dec 31, 2018 | 12,500 | 1,500 | 13.64% |
Dec 31, 2017 | 11,000 | 3,000 | 37.50% |
Dec 31, 2016 | 8,000 | 0 | - |
Dec 31, 2015 | 8,000 | 300 | 3.90% |
Dec 31, 2014 | 7,700 | 100 | 1.32% |
Dec 31, 2013 | 7,600 | 100 | 1.33% |
Dec 31, 2012 | 7,500 | 300 | 4.17% |
Dec 31, 2011 | 7,200 | 1,000 | 16.13% |
Dec 31, 2010 | 6,200 | -2,000 | -24.39% |
Dec 31, 2009 | 8,200 | 300 | 3.80% |
Dec 31, 2008 | 7,900 | -800 | -9.20% |
Dec 31, 2007 | 8,700 | 200 | 2.35% |
Dec 31, 2006 | 8,500 | 500 | 6.25% |
Dec 31, 2005 | 8,000 | -2,000 | -20.00% |
Dec 31, 2004 | 10,000 | 0 | - |
Dec 31, 2003 | 10,000 | -700 | -6.54% |
Dec 31, 2002 | 10,700 | -100 | -0.93% |
Dec 31, 2001 | 10,800 | -1,700 | -13.60% |
Dec 31, 2000 | 12,500 | 500 | 4.17% |
Dec 31, 1999 | 12,000 | -1,000 | -7.69% |
Dec 31, 1998 | 13,000 | -1,000 | -7.14% |
Dec 31, 1997 | 14,000 | -1,000 | -6.67% |
Dec 31, 1996 | 15,000 | 0 | - |
Dec 31, 1995 | 15,000 | -10,000 | -40.00% |
Dec 31, 1994 | 25,000 | -7,000 | -21.88% |
Dec 31, 1993 | 32,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
RVTY News
- 7 days ago - Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing - Business Wire
- 8 days ago - Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance - Business Wire
- 10 days ago - Revvity Announces FDA Clearance for First Automated Free Testosterone Test - Business Wire
- 4 weeks ago - Revvity to Present at J.P. Morgan Healthcare Conference - Business Wire
- 5 weeks ago - Safe Biopharma: Revvity's Recurring Revenues And Diagnostics - Seeking Alpha
- 5 weeks ago - Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst - Benzinga
- 2 months ago - Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK - Business Wire
- 2 months ago - Scale Biosciences and Revvity's BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells - Business Wire